Prescribing information

 

Visit the recordings below to see video clips from a webinar event held on 9th September 2020.

The Bradford CCG heart failure pathway: taking heart failure management into primary care

Dr Matt Fay talks through the LVSD pathway that he has been involved in re-designing for primary care, along with the healthcare community in Bradford.

 

Chronic heart failure management and treatment updates in 2020

Professor Roy Gardner talks about licensed treatments for chronic heart failure with reduced ejection fraction and how these have evolved over time.

 

Digital heart failure consultations: how can we conduct them effectively in primary care?

Dr Majid Akram talks about virtual consultations and considerations required when reviewing chronic heart failure patients in this manner.

Based on GMC principles and his own experiences, Dr Akram also shares his ‘VIDEO’ acronym to help you get the most out of your virtual consultations for your patients.

 

Indication: Entresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.1

GMC, General Medical Council; HFrEF, heart failure with reduced ejection fraction; LVSD, Left ventricular systolic dysfunction.

Reference

  1. Entresto Summary of Product Characteristics, 2020.
UK | December 2020 | 101184
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]